Clinical Trials
9 trialsNCT07366658 2026-01-26
NEUK203-13
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1 Not yet recruiting
NCT05608148 2025-11-18
Clinical Trial of GAIA-102 for Refractory/Relapse Neuroblastomas and Other Malignant Pediatric Solid Tumors
Kyushu University
Phase 1 Recruiting
NCT01430390 2025-06-11
In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT03549000 2024-12-13
A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.
Novartis
Phase 1 Terminated
NCT00014131 2023-10-04
Vaccine Therapy in Treating Patients With Kidney Cancer
Lisata Therapeutics, Inc.
Phase 1 Terminated
NCT04382352 2023-03-24
B002-101
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 1 Completed
NCT03383952 2017-12-27
A Clinical Study of CD19 Targeted CAR-T for Patients With CD19+ Lymphoma and Leukemia
Immune Cell, Inc.
Phase 1 Unknown
NCT03383965 2017-12-27
CD30 Targeted CAR-T in Treating CD30-Expressing Lymphomas
Immune Cell, Inc.
Phase 1 Unknown
NCT01349647 2016-01-05
Immunization With a Pentavalent Vaccine Composed of KLH-conjugates of GD2L, GD3L, Globo H, Fucosyl GM1, and N-Propionylated Polysialic Acid
Memorial Sloan Kettering Cancer Center
Phase 1 Completed